LOGIN  |  REGISTER
Terns Pharmaceuticals

LevelJump Healthcare Closes $900,000 Private Placement

June 15, 2023 | Last Trade: C$0.05 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - June 15, 2023) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, following receipt of TSXV approval, it has sold and closed the sale of 7,200,000 Units (each a "Unit") to an accredited investor at a subscription price of $0.125 per Unit for gross proceeds of $900,000.

Each Unit consists of one common share ("Common Share"), and one common share purchase warrant ("Warrant"), with each Warrant entitling the holder to purchase one common share in the capital of the Company at an exercise price of $0.20 per common share for a period of 24 months from the date of issuance.

The proceeds raised from the issuance of the Units are intended to be used for the Company's Alberta acquisition (see the Company's news releases dated November 16, 2022, and March 6, 2023) and for general working capital. The Company has paid a finder's fee of $63,000 to certain finders in conjunction with this placement. All securities issued in connection with this placement will be subject to a statutory hold period of four months and one from the closing date.

Early Warning Disclosure

Nadia Abdul Aziz and Malik M Easah (the "Acquiror") makes the following announcement in accordance with National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues and National Instrument 62-104 Take-Over Bids and Issuer Bids.

Pursuant to the closing of the placement, the Company issued to the Acquiror, and the Acquiror purchased from the Company 7,200,000 Units at a price of $0.125 per Unit for a purchase price of $900,000 in reliance on the prospectus exemption contained in section 2.10 of National Instrument 45-106 Prospectus Exemption (the "Acquisition").

Immediately prior to the Acquisition, the Acquiror beneficially owned and had control and direction over 1,450,000 Shares and 1,000,000 Warrants representing approximately 1.7% (2.8% on a partially diluted basis) of the then issued and outstanding shares. As a result of the Acquisition, the Acquiror beneficially owns and has control and direction over 8,650,000 Shares and 8,200,000 Warrants, representing approximately 9.2% (16.4% on a partially diluted basis) of the issued and outstanding Shares of the Company after closing of the Offering. The change in the Acquiror's security holding percentage is 7.5% (13.6% on a partially diluted basis) of the issued and outstanding Shares.

The Acquiror acquired the Units for investment purposes. The Acquiror will review its holdings from time to time and may, in the future, increase or decrease his ownership or control over securities of the Company as circumstances dictate.

An early warning report will be filed under the Company's profile on the SEDAR website at www.sedar.com.

About LevelJump Healthcare

LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its IHF's (Independent Healthcare Facilities). JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve.

ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.

Mitchell Geisler
Chief Executive Officer

Caitlin-Robyn Densmore
Investor Relations Manager
This email address is being protected from spambots. You need JavaScript enabled to view it.
(437) 214-1568

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB